Centrilobular Emphysema Is Associated with Pectoralis Muscle Reduction in Current Smokers without Airflow Limitation
- PMID: 36689922
 - PMCID: PMC10064397
 - DOI: 10.1159/000529031
 
Centrilobular Emphysema Is Associated with Pectoralis Muscle Reduction in Current Smokers without Airflow Limitation
Abstract
Background: Physiological and prognostic associations of centrilobular emphysema (CLE) and paraseptal emphysema (PSE) in smokers with and without chronic obstructive pulmonary disease (COPD) have been increasingly recognized, but the associations with extrapulmonary abnormalities, such as muscle wasting, osteoporosis, and cardiovascular diseases, remain unestablished.
Objectives: The aim of the study was to investigate whether CLE was associated with extrapulmonary abnormalities independent of concomitant PSE in smokers without airflow limitation.
Methods: This retrospective study consecutively enrolled current smokers without airflow limitation who underwent lung cancer screening with computed tomography and spirometry. CLE and PSE were visually identified based on the Fleischner Society classification system. Cross-sectional areas of pectoralis muscles (PM) and adjacent subcutaneous adipose tissue (SAT), bone mineral density (BMD), and coronary artery calcification (CAC) were evaluated.
Results: Of 310 current smokers without airflow limitation, 83 (26.8%) had CLE. The PSE prevalence was higher (67.5% vs. 23.3%), and PM area, SAT area, and BMD were lower in smokers with CLE than in those without (PM area (mean), 34.5 versus 38.6 cm2; SAT area (mean), 29.3 versus 36.8 cm2; BMD (mean), 158.3 versus 178.4 Hounsfield unit), while CAC presence did not differ. In multivariable models, CLE was associated with lower PM area but not with SAT area or BMD, after adjusting for PSE presence, demographics, and forced expiratory volume in 1 s.
Conclusions: The observed association between CLE and lower PM area suggests that susceptibility to skeletal muscle loss could be high in smokers with CLE even without COPD.
Keywords: Chest computed tomography; Chronic obstructive pulmonary disease; Emphysema; Muscle wasting.
© 2023 The Author(s). Published by S. Karger AG, Basel.
Conflict of interest statement
Naoya Tanabe, Susumu Sato, Tsuyoshi Oguma, and Toyohiro Hirai were supported by a grant from FUJIFILM Co., Ltd. Susumu Sato received grants from Nippon Boehringer Ingelheim, Philips Respironics, Fukuda Denshi, Fukuda Lifetec Keiji, and ResMed outside of the submitted work. None of these companies played a role in the design or analysis of the study or in the writing of the manuscript. The other authors have no conflicts of interest to declare.
Figures
              
              
              
              
                
                
                
              
              
              
              
                
                
                References
- 
    
- Lim SS, Vos T, Flaxman AD, Danaei G, Shibuya K, Adair-Rohani H, et al. A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990–2010 a systematic analysis for the global burden of disease Study 2010. Lancet. 2012;380((9859)):2224–2260. - PMC - PubMed
 
 - 
    
- Schaap LA, Pluijm SMF, Deeg DJH, Visser M. Inflammatory markers and loss of muscle mass (sarcopenia) and strength. Am J Med. 2006 Jun;119((6)):526.e9–617.e9. - PubMed
 
 - 
    
- Yanbaeva DG, Dentener MA, Creutzberg EC, Wesseling G, Wouters EFM. Systemic effects of smoking. Chest. 2007 May;131((5)):1557–1566. - PubMed
 
 - 
    
- Rabe KF, Watz H. Chronic obstructive pulmonary disease. Lancet. 2017;389((10082)):1931–1940. - PubMed
 
 
